Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Core Viewpoint - Repligen Corporation has announced a definitive agreement to acquire Tantti Laboratory Inc., enhancing its bioprocessing technology portfolio with Tantti's innovative macroporous chromatography bead technology for the purification of large molecule biologics [2][3]. Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing bioprocessing technologies that improve the manufacturing efficiency of biological drugs [11]. - Tantti Laboratory Inc. specializes in biomaterials engineering and has developed bioprocessing solutions, particularly the DuloCore technology for purifying large biomolecules [6][10]. Acquisition Details - The acquisition is expected to be completed by the end of 2024, pending regulatory approvals [3][9]. - The deal is anticipated to be breakeven on adjusted margins and adjusted earnings per share (EPS) in 2025, and accretive to adjusted margins and adjusted EPS in 2026 [9]. Technology Synergy - Tantti's DuloCore technology combines high throughput performance with rapid mass transfer in a bead format, which is expected to enhance purification processes when integrated with Repligen's existing AVIPure affinity ligands and OPUS pre-packed chromatography columns [1][3]. - The technology aims to address downstream bottleneck challenges and scalability concerns faced by manufacturers in the bioprocessing industry [1][3]. Leadership Statements - Repligen's CEO, Tony J. Hunt, emphasized that the acquisition will strengthen their portfolio in the new modality space and is expected to deliver high throughput and high-capacity purification products [3]. - Tantti's CEO, Joe Yang, expressed excitement about combining their bead technology with Repligen's capabilities to establish DuloCore as a market standard for new modality purification [3].